Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celsius Holdings, Inc.CELH · Entity 3658 | Director | September 14, 2026 | September 15, 2026 |
| INTEGRATED BIOPHARMA INCINBP · Entity 8227 | Director · 10% owner | June 24, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celsius Holdings, Inc.
Report date September 14, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 2,728,187 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-14 · Purchase · Acquired 20,000 · Balance 2,712,187 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $27.60 to $27.70, inclusive. The reporting person undertakes to provide Celsius Holdings, Inc. ("Celsius"), any security holder of Celsius, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Row 2 · 2026-09-15 · Purchase · Acquired 16,000 · Balance 2,728,187 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $27.9496 to $27.95, inclusive. The reporting person undertakes to provide Celsius Holdings, Inc. ("Celsius"), any security holder of Celsius, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $27.60 to $27.70, inclusive. The reporting person undertakes to provide Celsius Holdings, Inc. ("Celsius"), any security holder of Celsius, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $27.9496 to $27.95, inclusive. The reporting person undertakes to provide Celsius Holdings, Inc. ("Celsius"), any security holder of Celsius, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
INTEGRATED BIOPHARMA INC
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2036-06-24 | Direct | 50,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 15, 2026 20:17 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | PurchaseCommon Stock, $0.001 par value per share | 16,000 | $27.95 | $447,200.00 |
DisclosureSEC source: 0001628280-26-062057 · wk-form4_1789503449.xml · nonDerivative · entry 2 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,728,187 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $27.9496 to $27.95, inclusive. The reporting person undertakes to provide Celsius Holdings, Inc. ("Celsius"), any security holder of Celsius, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 20:17 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | PurchaseCommon Stock, $0.001 par value per share | 20,000 | $27.65 | $553,000.00 |
DisclosureSEC source: 0001628280-26-062057 · wk-form4_1789503449.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,712,187 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $27.60 to $27.70, inclusive. The reporting person undertakes to provide Celsius Holdings, Inc. ("Celsius"), any security holder of Celsius, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 16:07 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001345281-26-000008 · primary_doc.xml · derivative · entry 1 DeSantis Damon · CIK 0001889279 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-24 F1 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 15:21 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GiftCommon Stock | 2,235,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-26-000004 · primary_doc.xml · nonDerivative · entry 2 DeSantis Damon · CIK 0001889279 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CDDS 2.0, LLC Disclosed balance after: 12,733,058 F2 · kind: Represents 2,235,417 shares of Common Stock transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 15:21 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GiftCommon Stock | 8,966,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-26-000004 · primary_doc.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CDDS 2.0, LLC Disclosed balance after: 10,497,641 F1 · kind: Represents 8,966,547 shares of Common Stock transferred from CD Financial, LLC, a Florida limited liability company, to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 19:39 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GiftCommon Stock | 7,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-26-000001 · primary_doc.xml · nonDerivative · entry 2 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By CDDS 2.0, LLC Disclosed balance after: 1,363,685 F2 · kind: Represents 7,392 shares of Common Stock transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 19:39 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GiftCommon Stock | 1,356,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-26-000001 · primary_doc.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By CDDS 2.0, LLC Disclosed balance after: 1,356,293 F1 · kind: Represents 1,356,293 shares of Common Stock transferred from CD Financial, LLC, a Florida limited liability company, to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:15 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GrantCommon Stock, $0.001 par value per share | 2,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014143 · wk-form4_1772579723.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,692,187 F1 · shares: Consists of restricted stock units ("RSUs"), with each RSU providing for the right to receive one share of common stock, par value $0.001 per share, of Celsius Holdings, Inc. The RSUs fully vest on the first anniversary of the grant date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 18:12 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001345281-25-000009 · primary_doc.xml · derivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 17:06 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GrantCommon Stock, $0.001 par value per share | 4,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001341766-25-000037 · wk-form4_1741126000.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,689,576 F1 · shares: Consists of restricted stock units ("RSUs"), with each RSU providing for the right to receive one share of common stock, par value $0.001 per share, of Celsius Holdings, Inc. The RSUs fully vest on the first anniversary of the grant date. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 15:49 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001345281-24-000004 · primary_doc.xml · derivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-07 F1 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025. Read SEC document |
| May 29, 2024 Filed May 31, 2024 16:38 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GiftCommon Stock, $0.001 par value per share | 1,965,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001341766-24-000044 · wk-form4_1717187650.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,684,711 F1 · shares: The reported transaction represents the transfer of shares made as a gift for no consideration. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:57 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GrantCommon Stock, $0.001 par value per share | 1,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009088 · wk-form4_1709679443.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,723 F1 · security: Consists of restricted stock units ("RSUs"), with each RSU providing for the right to receive one share of common stock, par value $0.001 per share, of Celsius Holdings, Inc. The RSUs vest on the first anniversary of the grant date. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 19:27 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-23-000001 · primary_doc.xml · derivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-07-18 F1 · derivative.exercise_price: The exercise price of each stock option will be the closing price of the Issuer's Common Stock on July 25, 2023, which represents the fifth trading day after the grant date. F2 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024. Read SEC document |
| January 05, 2023 Filed Mar 27, 2023 16:46 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GiftCommon Stock | 232,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001829126-23-002290 · ownership.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,049 F1 · price: Represents a bona fide gift for no consideration. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 17:09 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GrantCommon Stock | 1,105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001829126-23-000458 · ownership.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 F1 · price: The reporting person was granted 1,105 RSUs for shares of common stock to be issued under the Issuer's 2015 Stock Incentive Plan. The RSUs shall vest on January 1, 2024. Read SEC document |
| June 20, 2022 Filed Jun 21, 2022 21:33 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-22-000002 · primary_doc.xml · derivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-20 F1 · derivative.exercise_price: The exercise price of each stock option will be the closing price of the Issuer's Common Stock on June 27, 2022, which represents the fifth trading day after the grant date. F2 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023. Read SEC document |
| January 01, 2022 Filed Feb 22, 2023 16:06 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GrantCommon Stock | 2,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001829126-23-001632 · ownership.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,055 F1 · price: Represents a grant of restricted stock units, all of which vested on December 31, 2022. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 16:53 UTC | Celsius Holdings, Inc. CELH · Entity 3658 | GrantCommon Stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001829126-21-013221 · ownership.xml · nonDerivative · entry 1 DeSantis Damon · CIK 0001889279 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 F1 · price: The reporting person was granted 2,750 restricted stock units (RSU) under the issuer's 2015 Stock Incentive Plan. The RSUs will vest on December 31, 2021. Each RSU represents a right to receive one share of Celsius Holdings, Inc. common stock upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.